Spyre Therapeutics (SYRE) Short Interest Ratio & Short Volume → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free SYRE Stock Alerts $33.87 +0.84 (+2.54%) (As of 05/1/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Spyre Therapeutics Short Interest DataCurrent Short Volume3,560,000 sharesPrevious Short Volume3,010,000 sharesChange Vs. Previous Month+18.27%Dollar Volume Sold Short$132.43 millionShort Interest Ratio / Days to Cover7.3Last Record DateApril 15, 2024Outstanding Shares36,150,000 sharesFloat Size33,730,000 sharesShort Percent of Float10.55%Today's Trading Volume670,894 sharesAverage Trading Volume452,146 sharesToday's Volume Vs. Average148% Short Selling Spyre Therapeutics ? Sign up to receive the latest short interest report for Spyre Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatSYRE Short Interest Over TimeSYRE Days to Cover Over TimeSYRE Percentage of Float Shorted Over Time Ad Porter & CompanyThe biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…For the full story, click here. Spyre Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20243,560,000 shares $132.43 million +18.3%10.6%7.3 $37.20 3/31/20243,010,000 shares $114.17 million +4.5%9.4%6 $37.93 3/15/20242,880,000 shares $130.67 million +34.0%9.0%6.4 $45.37 2/29/20242,150,000 shares $59.00 million +35.2%6.7%5.5 $27.44 2/15/20241,590,000 shares $35.87 million +123.6%5.0%5.8 $22.56 1/31/2024711,000 shares $18.42 million No Change2.1%3.8 $25.91 SYRE Short Interest - Frequently Asked Questions What is Spyre Therapeutics' current short interest? Short interest is the volume of Spyre Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 3,560,000 shares of SYRE short. 10.55% of Spyre Therapeutics' shares are currently sold short. Learn More on Spyre Therapeutics' current short interest. What is a good short interest ratio for Spyre Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SYRE shares currently have a short interest ratio of 7.0. Learn More on Spyre Therapeutics's short interest ratio. What is a good short interest percentage for Spyre Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.55% of Spyre Therapeutics' floating shares are currently sold short. Is Spyre Therapeutics' short interest increasing or decreasing? Spyre Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 3,560,000 shares, an increase of 18.3% from the previous total of 3,010,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Spyre Therapeutics' float size? Spyre Therapeutics currently has issued a total of 36,150,000 shares. Some of Spyre Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Spyre Therapeutics currently has a public float of 33,730,000 shares. How does Spyre Therapeutics' short interest compare to its competitors? 10.55% of Spyre Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Spyre Therapeutics: Ligand Pharmaceuticals Incorporated (4.98%), Pacira BioSciences, Inc. (7.42%), Kiniksa Pharmaceuticals, Ltd. (5.15%), Verona Pharma plc (7.51%), Pieris Pharmaceuticals, Inc. (0.03%), Deciphera Pharmaceuticals, Inc. (11.45%), Collegium Pharmaceutical, Inc. (22.86%), Ironwood Pharmaceuticals, Inc. (13.96%), AbCellera Biologics Inc. (11.25%), Mirum Pharmaceuticals, Inc. (18.21%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Spyre Therapeutics stock? Short selling SYRE is an investing strategy that aims to generate trading profit from Spyre Therapeutics as its price is falling. SYRE shares are trading down $0.28 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Spyre Therapeutics? A short squeeze for Spyre Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SYRE, which in turn drives the price of the stock up even further. How often is Spyre Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SYRE, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Ligand Pharmaceuticals Short Squeeze Pacira BioSciences Short Squeeze Kiniksa Pharmaceuticals Short Squeeze Verona Pharma Short Squeeze Pieris Pharmaceuticals Short Squeeze Deciphera Pharmaceuticals Short Squeeze Collegium Pharmaceutical Short Squeeze Ironwood Pharmaceuticals Short Squeeze AbCellera Biologics Short Squeeze Mirum Pharmaceuticals Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SYRE) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlaceThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing